Melezitose inhibited glycolytic pathway and enhances anti-Crohn's disease activity via binding to PGK1
This study revealed that Mel exerts its anti-inflammatory and reparative capabilities in vitro and in vivo by inhibiting the activity of the key glycolytic enzyme PGK1, leading to reduced production of ATP and its products 2-PG and 3-PG, thereby ameliorating the symptoms of CD. It can emerge as a promising candidate for CD treatment.
Authors
- Shulipan Mulati
- Junmin Chang (ORCID: https://orcid.org/0000-0003-3289-0602)
- Miaomiao Zhang
- Jianing Ma (ORCID: https://orcid.org/0000-0002-9515-4429)
- Weiyi Zhang
Institutions
- Xinjiang Medical University (CN)
- Xinjiang University (CN)
Publication Details
- Journal
- Journal of Ethnopharmacology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1016/j.jep.2025.119443
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- National Natural Science Foundation of China